![]() | |
Clinical data | |
---|---|
Trade names | Rapivab |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% (IV) |
Elimination half-life | 7.7 to 20.8 hours (in patients with normal renal function) |
Excretion | Kidney |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H28N4O4 |
Molar mass | 328.413 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Influenza (flu) |
---|
![]() |
Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.[2]
In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of peramivir based on safety data from phase I, phase II, and limited phase III trial data. The emergency use authorization for peramivir expired in June 2010.[3][4] On 19 December 2014, the FDA approved peramivir to treat influenza infection in adults.[2]
FDA approval
was invoked but never defined (see the help page).